Physician profile
Teri Lynn
NPI 1225129976
$4,318.43
in general payments reported to CMS, 2019-2025
39 companies · $854 in 2025
The $854 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,167 · 2022: $1,014 · 2023: $786 · 2024: $498 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $754.62 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $499.50 | 2021-2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.78 | 2021-2025 | Jardiance |
| Pfizer INC. | $395.33 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $350.08 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $247.15 | 2021-2025 | |
| Abbott Laboratories | $211.88 | 2021-2025 | Merlin@Home |
| United Therapeutics Corporation | $189.42 | 2023-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $178.15 | 2021-2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $149.43 | 2021-2025 | Verquvo, Winrevair |
| E.R. Squibb & Sons, L.L.C. | $117.61 | 2021-2023 | Eliquis |
| Lilly USA, LLC | $83.35 | 2021-2023 | Mounjaro |
| Novo Nordisk INC | $70.09 | 2022-2025 | Wegovy |
| Acacia Pharma INC | $56.92 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $41.48 | 2023 | Arcalyst |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teri Lynn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.